Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,275
Recruiting: 2,321
Ph III recruiting: 270
Growth YoY: +12.6%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,963)

clinicaltrialsPublishedShowing 601–650 of 2,851 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05985655	Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE)	recruiting	Phase 1 / Phase 2	230	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY	3	Aug 13, 2026	clinicaltrials
NCT06041503	Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)	recruiting	Phase 2	68	National Cancer Institute (NCI)NIH	1